



Published in final edited form as:

Biochemistry. 2009 November 24; 48(46): 11032–11044. doi:10.1021/bi901597j.

## Characterization of *cyclo*-Acetoacetyl-L-Tryptophan Dimethylallyltransferase in Cyclopiazonic Acid Biosynthesis: Substrate Promiscuity and Site Directed Mutagenesis Studies

Xinyu Liu and Christopher T. Walsh

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, MA. 02115

### Abstract

The fungal neurotoxin  $\alpha$ -cyclopiazonic acid (CPA), a nanomolar inhibitor of  $\text{Ca}^{2+}$ -ATPase with a unique pentacyclic indole tetramic acid scaffold is assembled by a three enzyme pathway CpaS, CpaD and CpaO in *Aspergillus sp.* We recently characterized the first pathway-specific enzyme CpaS, a hybrid two module polyketide synthase-nonribosomal peptide synthetase (PKS-NRPS) that generates *cyclo*-acetoacetyl-L-tryptophan (*cAATrp*). Here we report the characterization of the second pathway-specific enzyme CpaD that regiospecifically dimethylallylates *cAATrp* to form  $\beta$ -cyclopiazonic acid. By exploring the tryptophan and tetramate moieties of *cAATrp*, we demonstrate that CpaD discriminates against free Trp but accepts tryptophan-containing thiohydantoin, diketopiperazines and linear peptides as substrates for C4-prenylation and also acts as regiospecific *O*-dimethylallyltransferase (DMAT) on a tyrosine-derived tetramic acid. Comparative evaluation of CpaDs from *A. oryzae* RIB40 and *A. flavus* NRRL3357 indicated the importance of the N-terminal region for its activity. Sequence alignment of CpaD with eleven homologous fungal Trp-DMATs revealed five regions of conservation suggesting the presence of critical motifs that could be diagnostic for discovering additional Trp-DMATs. Subsequent site-directed mutagenesis studies identified five polar/charged residues and five tyrosine residues within these motifs that are critical for CpaD activity. This motif characterization will enable a gene probe-based approach to discover additional biosynthetic Trp-DMATs.

### INTRODUCTION

Prenylated indole alkaloids represent a large family of natural products that are produced by various terrestrial and marine organisms including plants, fungi, cyanobacteria and actinomyces (1). Fungi are the most prolific producers that biosynthesize an array of prenylated indole alkaloids with complex molecular architectures and profound biological activities, including postpartum haemorrhage prevention drugs ergometrine and ergotamine (2), antitumor agents tryprostatins (3) and stephacidins (4), antiparasitic agents paraherquamides (5), and mycotoxins aflatoxin (6) and cyclopiazonic acid (7).

\*Corresponding Author: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115. christopher\_walsh@hms.harvard.edu. Phone: 617-432-1715. Fax: 617-432-0438.

†This work was supported in part by National Institute of Health Grant GM20011 (to C.T.W.) and Swiss National Science Foundation and Ernst Schering Foundation (postdoctoral fellowships to X.L.).

Supporting Information Available: Tables S1–S3, Scheme S1 and Figures S1–S3. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Except for indole-diterpene alkaloids that use geranylgeranyl pyrophosphate as prenyl donor (8), dimethylallyl pyrophosphate (DMAPP) is the predominant prenyl source for fungal prenyl indole alkaloids. Dimethylallylation critically functionalizes indole alkaloid backbones by introducing structural complexity and profoundly influencing biological activity. Regioselective dimethylallylation of didemethylasterriquinone D with bisindolylbenzoquinone scaffold leads to a variety of asterriquinones including terrequinone A (9), cochliodinol (10) and asterriquinone CT5 (11) with distinct biological activities. Biosynthetic dimethylallylation provides a functional alkene and a set of allylic hydrogens that constitute the reactive center for subsequent enzymatic oxidations and cyclizations en route to the complex polycyclic frameworks observed in many prenylated indole alkaloids (12,13).

Dimethylallylation of scaffolds in fungal prenylated indole alkaloids is catalyzed by tryptophan dimethylallyltransferases (Trp-DMATs). Initially isolated from *Claviceps purpurea* (14), the characterization and sequencing of a C-4 Trp-DMAT (DmaW) involved in ergot alkaloid biosynthesis set the foundation for discovery and study of functionally related Trp DMATs (15,16). By a combination of recent advances in fungal genome sequencing with *in silico* bioinformatic and *in vitro* biochemical analyses six additional pathway-specific Trp-DMATs have been identified. These include FgaPT1 and FgaPT2 in fumigaclavine C biosynthesis (17), FtmPT1 and FtmPT2 in fomitremorgin B biosynthesis (18), TdiB in terrequinone A biosynthesis (19) and AnaPT in acetylazonalenin biosynthesis (20). Analogous efforts have resulted in the identification of three homologs, 7-DMATS (21), CdpNPT (22) and MaPT (23), in currently undefined biosynthetic pathways. All characterized fungal Trp-DMATs lack the conserved (N/D)DxxD and N(Q/D)xxDxxxD sequences for pyrophosphate binding in *trans*-polyprenyl pyrophosphate synthases and membrane bound aromatic prenyl transferases respectively (24). The combined biochemical results indicate that Trp-DMAT catalyzed dimethylallyl transfer does *not* require Mg<sup>2+</sup>, a characteristic that distinguishes the Trp-DMAT family of prenyl transferases.

The latest addition to the family of fungal prenylated indole alkaloid gene clusters is for biosynthesis of cyclopiazonic acid (CPA or  $\alpha$ -CPA), a potent neurotoxin with a rigid pentacyclic indole tetramate scaffold that acts as a nanomolar inhibitor of the sarcoplasmic Ca<sup>2+</sup> ATPase (25). The CPA biosynthetic genes *cpaS*, *cpaD* and *cpaO* were recently identified in *Aspergillus sp.* by a combined bioinformatic and genetic approach (26,27) and correlate well with previous predictions that the CPA scaffold is derived from two intermediates, *cyclo*-acetoacetyl L-tryptophan (*cAATrp* or L-*cAATrp*) and  $\beta$ -CPA, which are assembled from tryptophan, two molecules of acetate, and DMAPP (Figure 1) (28). We recently reported the detailed study of CpaS, a hybrid two module polyketide synthase-nonribosomal peptide synthetase (PKS-NRPS) that incorporates acetyl CoA, malonyl CoA, and tryptophan and utilizes a C-terminal redox-incompetent reductase domain to make and release the tryptophan tetramic acid, *cAATrp*, as the first intermediate in the pathway (29).

CpaD is proposed to be a C-4 Trp-DMAT that tailors *cAATrp* with DMAPP to generate  $\beta$ -CPA in the second step of the pathway (Figure 1A). Since tetramic acid moieties in related natural products often serve as the pharmacophore for recognition by a range of biological targets (30), we speculated that this ring would be an important recognition element for CpaD as well. Here we validate the role of CpaD in the CPA biosynthetic pathway by showing that while it is essentially inactive with free tryptophan, it can act as a C-4 DMAT towards Trp-containing thiohydantoin, diketopiperazines and linear peptides, and as an *O*-DMAT on a tyrosine-derived tetramic acid. Comparison of CpaD with eleven other fungal Trp-DMATs led us to a detailed mutagenesis study in which we identified ten critical residues within five conserved motifs that are catalytically consequential to the activity of CpaD.

## EXPERIMENTAL PROCEDURES

### General methods and materials

Standard molecular biology procedures were performed as described (31). Oligonucleotide primers were synthesized by Integrated DNA Technologies (Coralville, IA). PCR was performed either using KAPA HiFi DNA polymerase (KAPA Biosystems) or Fusion high fidelity DNA polymerase (New England Biolabs) under suggested conditions on a BioRAD MyCycler™ thermocycler. For general cloning, *E. coli* NovaBlue(DE3) cells (Novagen) were used. DNA sequencing was performed at the Molecular Biology Core Facilities of the Dana Farber Cancer Institute (Boston, MA). The strain and genomic DNA from *Aspergillus oryzae* RIB40 (ATCC 42149) were obtained from American Type Culture Collection (ATCC). The strain and genomic DNA from *Aspergillus flavus* NRRL3357 were obtained from Dr. K. McCluskey (FGSC) and Dr. J. Yu (USGA). *Penicillium cyclopium* (i.e. *Penicillium griseofulvum* Dierckx) strain NRRL 3523 was obtained from Dr. S. Peterson (USGA). Dimethylallylpyrophosphate (DMAPP) and related isoprenoid pyrophosphates were obtained from Isoprenoids LC. Tryptophan-containing dipeptides and thiohydantoin were purchased from Research Organics and Chem-Impex, Inc. Tryptophan-containing oligopeptides were synthesized by Peptide 2.0 (purity > 98%). All other chemicals were obtained from Sigma-Aldrich. HPLC was performed on a Beckman System Gold (Beckman Coulter) instrument using Phenomenex Luna C18 columns (250 × 4.5 mm, for analytical purpose; 250 × 21.6 mm, for preparative purpose). The eluant was monitored for absorption at 280 nm for all LC analysis of tryptophan derivatives. A 3%–97% acetonitrile/water gradient over 30 min was used for analytical HPLC assay, unless otherwise noted. LC-MS analysis was carried out on a Shimadzu LCMS-QP8000a (low resolution) and an Agilent 6520 QTOF-LCMS (high resolution) machines. <sup>1</sup>H NMR spectra were recorded on a Varian 600 MHz spectrometer. Chemical shifts are reported in ppm with the solvent resonance resulting from incomplete deuteration as the internal standard (CDCl<sub>3</sub> δ7.26, CD<sub>3</sub>OD δ3.31). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, br = broad, m = multiplet), coupling constants (Hz), and integration.

### Cloning, overproduction and purification of CpaD

The protein-coding exons of *cpaD* genes from *A. oryzae* RIB40 were amplified individually from genomic DNA using the oligonucleotide primers listed in Table S1 (Supporting information). The amplified exons were gel-purified, overlap-extended to yield the full-length *cpaD* gene and subsequently ligated into the *Bam*HI and *Not*I sites of expression vector pQTEV (Protein Structure Factory) using DNA ligation kit Ver 2.1 (Takara). This gave the expression vector pQTEV::*cpaD*, which was subsequently sequence-verified and transferred into *E. coli* DE3 (Star) competent cells for protein expression. Cells were cultured in Luria Bertani medium containing 100 µg/mL of Ampicillin. A fresh overnight culture from a single colony was used to inoculate 2 × 1L medium. Cells were grown at 37 °C in a shaker at 200 rpm till mid-log phase ( $A_{600} \approx 0.5$ ). The cultures were then cooled to 16 °C and induced by isopropyl β-D-1-thiogalactopyranoside with a final concentration of 0.25 mM. The cultures were allowed to further grow at 16 °C for 12–16 h. The cells were harvested by centrifugation and cell pellets from the 2L culture were resuspended in a buffer (50 mL) containing 20 mM Tris-HCl pH 8, 500 mM NaCl, 20 mM imidazole, 1mM DTT, 0.5% (v/v) Tween-20, and homogenized. The homogenized cells were lysed by passing through a cell disruptor (Avestin EmulsiFlex-C5) three times at 5000–10,000 psi, and the lysate was clarified by ultracentrifugation (35,000 rpm × 35 min). The supernatant was incubated with 2 mL of Ni-NTA-agarose resin (Qiagen) at 4 °C for 1 h and loaded to a column. The resin was then washed with a buffer (20 mL) containing 20 mM Tris-HCl pH 8, 500 mM NaCl, 20 mM imidazole. His<sub>7</sub>-tagged CpaD was eluted with 20 mL of 200 mM imidazole in 20 mM Tris-HCl pH 8, 500 mM NaCl. The protein was further purified by gel filtration chromatography using a HiLoad 26/60 Superdex 200 column (GE

Biosciences) with a buffer containing 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 1mM DTT, 5% glycerol. Fractions containing CpaD were pooled and concentrated using Amicon Ultra centrifugal filter device (Millipore). The protein concentration was determined by Bradford assay and the protein's absorbance at 280 nm with molar extinction coefficient 72310  $M^{-1}cm^{-1}$  (predicted using ProtParam <http://ca.expasy.org/tools/protparam.html>). Proteins were flash-frozen in aliquots in liquid nitrogen and stored at  $-80^{\circ}C$  for further usages. The overproduction yield was ca. 25 mg/L for CpaD from *A. oryzae* RIB40. The cloning of the original and revised *cpaD* genes from *A. flavus* NRRL3357 were carried out in a similar fashion with the oligonucleotides listed in Table S1 (supporting information). Subsequent protein overexpression gave purified CpaD in a yield 0.2 mg/L for originally assigned CpaD from *A. flavus* NRRL3357 and 20 mg/L for revised CpaD from *A. flavus* NRRL3357.

### Synthetic substrates preparation

*cyclo*-Acetoacetyl L-tryptophan (L-*cAA*Trp) was prepared as previously described (29). The corresponding stereoisomer *cyclo*-acetoacetyl D-tryptophan (D-*cAA*Trp) was synthesized in the same manner, using D-tryptophan methylester hydrochloride as the starting material instead of L-tryptophan methylester hydrochloride. All spectral data of D-*cAA*Trp matched those of *cyclo*-L-*cAA*Trp.  $[\alpha]_D^{24} = 118.2$  ( $c = 0.36$ , MeOH). L-tyrosine derived tetramic acid **10** was also synthesized in an analogous fashion as illustrated in Scheme S1 (Supporting Information). Briefly, *O*-*tert*-butyl-L-tyrosine methyl ester hydrochloride was acetoacetylated using *S*-*tert*-butyl acetothioacetate and silver trifluoroacetate in THF. Treatment of the derived product with sodium methoxide afforded the tetramate moiety, and deprotection of the *tert*-butyl tyrosine hydroxyl was removed by exposure to pure trifluoroacetic acid.  $[\alpha]_D^{24} = -168$  ( $c = 1.05$ , MeOH).  $^1H$  NMR (600 MHz,  $CD_3OD$ )  $\delta$  7.16 (d, 2H,  $J = 7.8$  Hz), 6.89 (d, 2H,  $J = 7.8$  Hz), 4.81 (dd, 1H,  $J = 7.8, 5.4$  Hz), 3.31 (dd, 1H,  $J = 14.0, 5.4$  Hz), 3.08 (dd, 1H,  $J = 14.0, 7.8$  Hz), 2.03 (s, 3H). HRMS (ESI): Calcd for  $C_{13}H_{13}N_2O_4$   $[M - H]^-$ : 246.0766, Found: 246.0761.

### Generation of *cAA*Trp, $\beta$ -CPA and $\alpha$ -CPA standards from *P. cyclopium* culture

The presence of *cAA*Trp and  $\beta$ -CPA as the biosynthetic intermediates of  $\alpha$ -CPA in the culture medium of *P. cyclopium* was previously observed (32). Since our primary focus was to obtain  $\beta$ -CPA as a reference material for the subsequent enzymatic assay, the described condition was optimized to maximize the production of  $\beta$ -CPA. Both *cAA*Trp and  $\alpha$ -CPA were isolated as minor products. Complete synthetic medium as described by McGrath et al. (32) was used for culturing *P. cyclopium* and prepared as follows: glucose (60 g),  $NaNO_3$  (4.5 g),  $K_2HPO_4$  (1 g),  $MgSO_4 \cdot 7H_2O$  (0.5 g), KCl (0.5 g),  $FeSO_4 \cdot 7H_2O$  (10 mg),  $ZnSO_4 \cdot 7H_2O$  (17.6 mg),  $Na_2B_4O_7 \cdot 10H_2O$  (0.7 mg),  $(NH_4)_6Mo_7O_{24} \cdot 4H_2O$  (0.5 mg),  $CaSO_4 \cdot 5H_2O$  (0.3 mg), and  $MnSO_4 \cdot H_2O$  (0.11 mg) were dissolved in 1 L of water. The pH was adjusted to 5.5 and then autoclaved for 20 min. A 4-day-old potato dextrose agar plate of *P. cyclopium* was flooded with a sterile aqueous solution of 0.001% Triton-X. The spore suspension obtained in this way was used to inoculate 30 mL of the complete synthetic medium in a 250 mL Erlenmeyer flask. The culture was maintained on a rotary shaker (170 rpm) at  $25^{\circ}C$  for 3.5 days (longer than 4 days resulted in predominant production of  $\alpha$ -CPA). The mycelia were removed by filtration, and the filtrate was acidified to  $pH \approx 2$  using concentrated HCl and extracted with chloroform. The combined organic layers were washed with water, dried over  $Na_2SO_4$  and evaporated to dryness to give a mixture containing *cAA*Trp,  $\beta$ -CPA and  $\alpha$ -CPA as shown in Figure 2B (lane 1). The identities of each metabolite were further verified by LC-MS analysis: *cAA*Trp,  $[M + H]^+$  cal for  $C_{15}H_{14}N_2O_3$ : 271.1083, obs: 271.1081;  $\beta$ -CPA,  $[M + H]^+$  cal for  $C_{20}H_{22}N_2O_3$ : 339.1709, obs: 339.1711;  $\alpha$ -CPA,  $[M + H]^+$  cal for  $C_{20}H_{20}N_2O_3$ : 337.1552, obs: 337.1553.

### Assays for CpaD activity

The initial assay to verify the function of CpaD was carried out in 100  $\mu\text{L}$  in 50 mM Tris•HCl (pH 7.5) buffer containing 0.25 mM *c*AATrp, 0.30 mM DMAPP and 0.1  $\mu\text{mol}$  of purified CpaD. The reaction mixture was incubated at 30 °C for 1 h and stopped by the addition of MeOH (100  $\mu\text{L}$ ). The quenched mixture was mixed thoroughly and centrifuged at the maximum speed using a bench top centrifuge for 10 min at 4 °C. The supernatant (160  $\mu\text{L}$ ) was subjected to HPLC and LC-MS analysis. For evaluating the effect of divalent metal on the activity of CpaD, the assays were carried out in 50  $\mu\text{L}$  in 50 mM Tris•HCl (pH 7.5) buffer containing 0.25 mM *c*AATrp, 0.25 mM DMAPP with selected divalent ion solution or EDTA (5 mM). The assay was initiated by adding 20 nmol of purified CpaD and quenched after 10 min with MeOH (50  $\mu\text{L}$ ). Assays were carried out in duplicate, and the conversion rate was calculated based by HPLC analysis and compared to the assay using CpaD enzyme without any exogenous divalent ion present.

### Substrate specificity of CpaD

For evaluating the substrate specificity of CpaD toward isoprenoid pyrophosphates other than DMAPP, initial assay conditions were used as above but with replacement of DMAPP with IPP, GPP, FPP and GGPP individually. Assays were conducted for an extended period (up to 16 h) to ensure even low turnover would be detected. For study of CpaD activity on tryptophan-containing thiohydantoins, DKPs, dipeptides and tyrosine-derived tetramic acid, the assay was carried out in 50  $\mu\text{L}$  in 50 mM Tris•HCl (pH 7.5) buffer containing 0.25 mM tryptophan derivative or tyrosine-derived tetramic acid, 0.30 mM DMAPP and 1  $\mu\text{mol}$  of purified CpaD. The reaction mixture was incubated at 30 °C for 15–16 h and stopped by the addition of MeOH (50  $\mu\text{L}$ ). After centrifugation, the supernatant was subjected to HPLC and high resolution LC-MS analysis to verify the identities of the products.

### Structural characterization of dimethylallylated tryptophan containing thiohydantoins, DKPs, dipeptides and tyrosine tetramic acids

To verify the regioselectivity of CpaD-mediated dimethylallylation of tryptophan-containing thiohydantoins (**1–3**), DKPs (**4–8**), dipeptides (**9–14**) and tyrosine tetramic acid **15**, assays using representative substrates **1**, **5**, **9**, **15** were scaled up and the corresponding products **1a**, **5a**, **9a**, **15a** were isolated for  $^1\text{H}$  NMR analysis. Briefly, the assays were carried out in a 4  $\times$  1 mL scale in 50 mM Tris•HCl (pH 7.5) buffer containing 0.5 mM *c*AATrp, 0.6 mM DMAPP and 2  $\mu\text{mol}$  of purified CpaD. The reaction mixture was incubated at 30 °C for 24 h and stopped by the addition of MeOH (4  $\times$  1 mL). The reaction mixture was subjected to preparative HPLC and peaks were collected for  $^1\text{H}$  NMR analysis. For **1a**,  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.95 (brs, 1H), 7.21 (d, 1H,  $J = 7.5$  Hz), 7.18 (s, 1H), 7.13 (d, 1H,  $J = 7.5$  Hz), 6.96 (*app.* t, 1H,  $J = 7.5$  Hz), 5.96 (brs, 1H), 5.75 (*app.* t, 1H,  $J = 6.5$  Hz), 4.01 (dd, 1H,  $J = 7.8, 5.4$  Hz), 3.35 (s, 1H), 3.31 (d, 1H,  $J = 14.0, 5.4$  Hz), 3.07 (d, 1H,  $J = 14.0, 5.4$  Hz), 1.83 (s, 3H), 1.71 (s, 3H). For **5a**,  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.01 (brs, 1H), 7.41 (m, 2H), 7.30 (m, 2H), 7.28 (m, 1H), 7.21 (d, 1H,  $J = 7.5$  Hz), 7.17 (s, 1H), 7.09 (d, 1H,  $J = 7.5$  Hz), 6.92 (*app.* t, 1H,  $J = 7.5$  Hz), 5.96 (brs, 1H), 5.75 (*app.* t, 1H,  $J = 6.5$  Hz), 4.16 (dd,  $J = 8.2, 5.6$  Hz), 4.01 (dd, 1H,  $J = 7.8, 5.4$  Hz), 3.42 (d, 1H,  $J = 14.2, 5.6$  Hz), 3.33 (d, 1H,  $J = 14.0, 5.4$  Hz), 3.42 (d, 1H,  $J = 14.2, 5.6$  Hz), 3.05 (d, 1H,  $J = 14.0, 5.4$  Hz), 1.83 (s, 3H), 1.71 (s, 3H). For **9a**,  $^1\text{H}$  NMR (600 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  7.22 (d, 1H,  $J = 7.5$  Hz), 7.17 (s, 1H), 7.12 (d, 1H,  $J = 7.5$  Hz), 6.99 (*app.* t, 1H,  $J = 7.5$  Hz), 5.75 (*app.* t, 1H,  $J = 6.5$  Hz), 4.39 (q, 1H,  $J = 6.8$  Hz), 4.00 (dd, 1H,  $J = 7.8, 5.4$  Hz), 3.31 (m, 1H), 3.02 (d, 1H,  $J = 14.0, 5.4$  Hz), 1.83 (s, 3H), 1.71 (s, 3H), 1.42 (d, 3H,  $J = 6.8$  Hz). For **15a**,  $^1\text{H}$  NMR (600 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  7.21 (d, 2H,  $J = 7.8$  Hz), 6.99 (d, 2H,  $J = 7.8$  Hz), 5.35 (t, 1H,  $J = 6.3$  Hz), 4.82 (dd, 1H,  $J = 7.8, 5.4$  Hz), 4.69 (d, 2H,  $J = 6.6$  Hz), 3.33–3.30 (m, 1H), 3.09 (dd, 1H,  $J = 14.0, 7.8$  Hz), 2.03 (s, 3H), 1.84 (s, 3H), 1.70 (s, 3H).

## Kinetic parameters of CpaD toward L-cAATrp, D-cAATrp, L-Trp, D-Trp and other substrates (1–15)

For calculating the kinetic parameters of CpaD towards its native substrate, L-cAATrp, the assay was conducted in 50  $\mu$ L in 50 mM Tris-HCl (pH 7.5) with 250  $\mu$ M DMAPP and varied concentration of L-cAATrp (5–500  $\mu$ M). The reaction was initiated at 30 °C by the addition of 10 nmol of purified CpaD (from *A. oryzae*). The reaction was quenched after 10 min with MeOH (100  $\mu$ L). The quenched mixture was mixed thoroughly and centrifuged at the maximum speed using a bench top centrifuge for 10 min at 4 °C. The supernatant (80  $\mu$ L) was subjected to HPLC analysis. Product quantification was based on integration of the 280 nm absorption peaks. Assays were run in duplicate and the data fit to the Michaelis-Menten equation using GraphPad Prism software. For D-cAATrp, the assay was carried out in the same manner except 100 nmol of purified CpaD were used to initiate the reaction. The relative turnover numbers of CpaD towards L-Trp and D-Trp were estimated based on the conversion rate using 250  $\mu$ mol L-Trp or D-Trp with 12  $\mu$ mol CpaD after a 16 h incubation. For calculating the kinetic parameters of CpaD towards substrates 1–15, the assays were carried out in a similar fashion as that for L-cAATrp, except 1  $\mu$ mol CpaD was used to initiate the reaction and substrates (1–15) concentration were varied up to 1 mM. For 9–14, saturation kinetics could not be achieved even with 1 mM substrate concentration; therefore the initial apparent maximum velocities were obtained when using 0.25 mM substrate, 0.25 mM DMAPP, 1  $\mu$ M CpaD at 30 °C.

## Generation of CpaD mutant proteins and their enzymatic activity assays

The mutants of *cpaD* were generated according to the protocol described in Stratagene QuikChange® Multi Site-Directed Mutagenesis Kit, using plasmid pQTEV::*cpaD* as the template and primers listed in Table S2 (supporting information). Primer oligonucleotides were *in situ* 5'-phosphorylated using T4 polynucleotide kinase (New England Biolab). Correct mutant plasmids were verified by sequencing. The mutant proteins were overproduced and purified in the same manner as that described for the wild type CpaD. The protein concentrations were measured using a Nanodrop device (Thermo Scientific) based on the absorbance at 280 nm with the predicted molar extinction coefficient. Except for mutants CpaD W33F, W33L, D119L, all other mutant proteins were overproduced as highly soluble as the wild type protein and isolated in ca. 15–30 mg/mL yields. Mutants W33F was isolated in ca 0.2 mg/mL, whereas W33L and D119L were not soluble. To compare the activities of mutant proteins with wild type, assays were carried out in 50  $\mu$ L in 50 mM Tris-HCl (pH 7.5) with 250  $\mu$ M L-cAATrp and 250  $\mu$ M DMAPP at 30 °C. The reaction was initiated by the addition of 50 nmol of purified CpaD wild type or mutant protein. The reaction was quenched at an optimal time point in order to obtain the maximum initial velocity. All assays were run in duplicate.

## RESULTS

### Cloning and overexpression of CpaD

The gene that codes DMAT CpaD responsible for  $\beta$ -CPA biosynthesis was initially disclosed in *A. oryzae* A1560 strain (33). BLAST analysis revealed an identical gene in *A. oryzae* RIB40 strain and subsequently led to the discovery of truncated and full CPA gene clusters in *A. oryzae* RIB40 and *A. flavus* NRRL3357, respectively (26,27). We first cloned the *cpaD* gene from *A. oryzae* RIB40 genomic DNA in an effort to correlate its function with CPA biosynthesis *in vitro* and the overproduced CpaD *A. oryzae* RIB40 protein is used throughout this study unless otherwise noted. The two protein coding exon fragments (1154 bp and 157 bp) were amplified individually and overlap-extended to generate the full length *cpaD* (1311 bp) followed by insertion into the pQTEV vector to afford the N-terminal His<sub>7</sub>-tagged CpaD expression construct. Overexpression in *E. coli* gave highly soluble CpaD (see methods), which

was subsequently purified to apparent homogeneity using successive nickel-affinity and gel filtration chromatographies (Figure 2A). CpaD appears homodimeric in solution based on its retention time on size exclusion chromatography.

### Validation of the function of CpaD

To assess the function of CpaD, we chemically synthesized the putative substrate L-*c*AATrp and isolated an authentic sample of  $\beta$ -CPA mixed with minor amount of  $\alpha$ -CPA and L-*c*AATrp from the native producer, *Penicillium cyclopium* NRRL 3523, as the reference material (see methods). Incubation of L-*c*AATrp and DMAPP with CpaD at 30 °C led to the rapid formation of a new peak by HPLC analysis that corresponds to  $\beta$ -CPA (Figure 2B). The identity of this new peak was assured to be  $\beta$ -CPA by co-elution with the isolated standard and high resolution MS analysis ( $[M+H]^+$  cal for  $C_{20}H_{22}N_2O_3$ : 339.1709, obs: 339.1713). We further examined if the activity of CpaD depends on the presence of divalent ion, a hallmark of *cis*- and *trans*-prenyltransferases (34–36). At 5 mM concentrations, we did not observe any statistically significant rate enhancement by inclusion of  $Ca^{2+}$  and  $Mg^{2+}$  (Figure 2C), as occasionally observed for other tryptophan DMATs (24). Other examined divalent ions, including  $Zn^{2+}$ ,  $Mn^{2+}$ ,  $Co^{2+}$ ,  $Ni^{2+}$  and  $Cu^{2+}$ , had moderate to profound inhibitory effects on the activity of CpaD (Figure 2C). Furthermore, the activity of CpaD was not influenced by the addition of EDTA (5 mM), ruling out the possible presence of endogenous metal cofactor. Consequently, all the assays using CpaD involved in this study were carried out without addition of divalent ions.

### Activity of CpaD towards D-*c*AATrp, L-/D-Trp and other isoprenoid pyrophosphates

With the basic function of CpaD verified, we compared the kinetic profiles of CpaD towards its native substrate, L-*c*AATrp, and its stereoisomer, D-*c*AATrp. The  $K_M$  value for L-*c*AATrp was determined to be  $109 \pm 16 \mu M$  with  $k_{cat}$   $53 \pm 12 \text{ min}^{-1}$  (Table 1). This corresponds to ca.  $0.48 \mu M^{-1} \text{ min}^{-1}$  in catalytic efficiency, a value comparable to most of the tryptophan DMATs characterized to date with their genuine substrates (24). In comparison, the catalytic efficiency of CpaD with D-*c*AATrp is about 24 fold lower than that with L-*c*AATrp, in accordance with other characterized Trp-DMATs that prefer L- over D-isomers (24). CpaD had extremely low activity towards the free amino acid L-Trp. Since we could not obtain saturation for L-Trp even at 1 mM concentration, the approximate turn over number was estimated to be  $4.1 \times 10^{-3} \text{ min}^{-1}$ , which implies the catalytic efficiency of CpaD for L-Trp is at least  $10^5$  fold less in comparison with L-*c*AATrp, and clearly not a physiologic substrate. The dramatic difference in catalytic efficiency of CpaD between L-*c*AATrp and L-Trp exceeds that observed for FtmPT1, the first committed Trp-DMAT involved in fumitremorgin B biosynthesis (18). FtmPT1 is a genuine C-2 Trp-DMAT for diketopiperazine *cyclo*-L-Trp-L-Pro (brevianamide F), but still can accept L-Trp with 675 fold decrease in catalytic efficiency (37). These combined observations indicate the tetramic acid portion of the L-*c*AATrp scaffold is an important recognition element for CpaD. Not surprisingly, the activity of CpaD towards D-Trp is even lower (Table 1). We also examined if CpaD utilizes other naturally occurring isoprenoid pyrophosphates including IPP, GPP, FPP and GGPP as prenyl donors. Even after an extended incubation time and increased enzyme concentration, no turnover was detected using these pyrophosphate substrates (data not shown), suggesting CpaD strictly utilizes DMAPP as the sole prenyl donor.

### Activity of CpaD towards tryptophan-containing thiohydantoin and diketopiperazines (DKPs)

Our initial experiments indicated that CpaD, unlike other characterized C-4 Trp-DMATs including FgaPT2 (38), DmaW (39) and MaPT (23), kinetically disfavors L-Trp and its simple derivatives such as L-abrine and methyl substituted L-Trp as substrates (data not shown). We

envisioned CpaD might have a distinctive substrate preference that could be useful for chemoenzymatic preparations of more complex dimethylallylated tryptophan containing molecules and sought to explore it in a systematic manner.

Bearing in mind that the tetramic acid portion of L-cAATrp is a key motif recognized by CpaD, we turned our initial attention to the readily available tryptophan-containing thiohydantoin derivatives **1–3** (Figure 3A), a family of necroptosis inhibitors (40). We speculated the 5-membered heterocyclic thiohydantoin would serve as a tetramate mimic (Figure 3A). Incubation of **1** with equal molar amount of DMAPP and 0.4 mol% CpaD overnight led to the clean formation of a new peak that corresponds to the dimethylallylated product **1a** (Figure 3C, lane 1–2). The dimethylallylation site was unequivocally assigned to be the C-4 position of indole ring by comparing the <sup>1</sup>H NMR of **1** with **1a** (see methods). Analogously, CpaD also accepts tryptophan thiohydantoin **2** and **3** as substrates and showed slight overall preference for **2** (Table 2, entries 1–3). Subsequent kinetic profiling indicated the K<sub>M</sub> values of CpaD for **1–3** increased only 3–5 fold in comparison with the native substrate L-cAATrp, but the corresponding *k*<sub>cat</sub> values drop 150–380 fold, resulting in a 500–2000 fold decrease in catalytic efficiency (Table 2, entries 1–3). While **1–3** are all racemic, based on our and others' observations that Trp-DMATs strongly prefer the L-isomer, **1–3** derived from L-Trp are most likely the preferred substrates for CpaD.

Given the above results using hydantoin substrates, the question arose of how the addition of one methylene unit to the 5 membered hydantoin scaffold, resulting in the 6-membered heterocycle diketopiperazine (DKP), would affect recognition by CpaD. The tryptophan containing DKP is one of the most prevalent scaffold elements in fungal prenylated indole alkaloids, including tryptostatin (**3**), echinullin (**41**) and fumitremorgin (**42**). However no natural product with C-4 prenylated Trp-containing DKP moieties have been discovered to date. The five Trp-derived DPKs **4–8** (Figure 3B) were analyzed for activity with CpaD (Table 2, entries 4–8). An HPLC assay using the Trp-Phe DKP **5** and 0.4 mol% CpaD (Figure 3C, lane 3–4) indicated ready conversion to the corresponding dimethylallylated product **5a**; the identity of the product and the C-4 regioselectivity of the prenylation site was unambiguously determined by high resolution mass spectrometry (Table 2) and NMR spectroscopy (see methods). However, kinetic analysis indicates that CpaD disfavors DKP substrates over hydantonins as the catalytic efficiency towards *enantiopure* L-Trp-Gly DKP **4** is only quarter of that to *racemic* thiohydantoin **2** (Table 2). Introduction of aromatic residues to the inserted methylene unit, corresponding to the L-Trp-L-Phe **5**, L-Trp-L-Tyr **6** and L-Trp-L-Trp **7** DKPs, increased the overall efficiency slightly to 110%, 140% and 30%, respectively, that of the L-Trp-Gly DKP **4** (Table 2,5–7). The constrained DKP L-Trp-L-Pro **8** was the least favorable substrate for CpaD among the five DKPs tested. Although the overall catalytic efficiencies of CpaD toward Trp-derived DKPs are not high, they are slightly superior to FgaPT2, a genuine C-4 Trp-DMAT that was recently shown to accept DKPs as substrates. Another C-4 Trp-DMAT, MaPT, was also shown to accept DKP **8** as a substrate (23); however, we could not carry the comparison further as MaPT has not been kinetically characterized for **8**.

### Activity of CpaD towards tryptophan-containing peptides

In contrast to the prevalence of prenylated cyclic tryptophan containing peptides, mostly as DKPs, the occurrence of prenylated tryptophan-containing linear peptides are rather rare in nature (43).<sup>1</sup> Several characterized Trp-DMATs have been shown to have broad substrate specificities to tailor L-Trp and L-Trp-containing DKP scaffolds (44); however, and rather

<sup>1</sup>The only known example is the *Bacillus subtilis* quorum-sensing peptide pheromone ComX, where the C-3 position of Trp is farnesylated or geranylated (44).



surprisingly, they all have considerable tryptophan aminopeptidase activity that render them unsuitable for chemoenzymatic preparation of L-Trp-containing linear peptides (45).

As an initial test, the dimethylallylation activity of CpaD was evaluated towards the dipeptide H-Trp-Ala-OH **9**, a superior aminopeptidase substrate for several Trp-DMATs characterized previously. With assay conditions analogous to those for Trp-containing thiohydantoin and DKPs, CpaD effected the quantitative conversion of H-Trp-Ala-OH **9** to the corresponding C-4 Trp dimethylallylated dipeptide **9b** (Figure 4), which was verified by high resolution MS (Table 3) and  $^1\text{H}$  NMR (see methods). It is noteworthy that CpaD did *not* show measurable peptidase activity towards **9** as had been observed with other Trp-DMATs including 7-DMATS, FgaPT1, CdpNPT, and FtmPT1. To further examine if this is unique to CpaD as a C-4 Trp-DMAT, we cloned and overproduced FgaPT2, a known C-4 Trp-DMAT that accepts L-Trp as genuine substrate with negligible aminopeptidase activity as originally reported by Li and coworkers (45). Incubation of FgaPT2 with H-Trp-Ala-OH **9** under the identical conditions for CpaD resulted in a new peak by HPLC analysis that corresponds to C-4 dimethylallylated L-Trp **9b** (Figure 4) as verified by MS analysis and HPLC co-elution with authentic **9b** generated from L-Trp and DMAPP with FgaPT2. This result suggests FgaPT2 may also harbor aminopeptidase activity that degrades **9** to L-Trp, which is preferentially prenylated by FgaPT2.

Five additional N-terminal Trp-containing dipeptides **10–14** were evaluated and confirmed to be CpaD substrates by combined LC-MS analysis of the prenylated dipeptide products (Table 3), whereas FgaPT2 affords the amino acid monomer **9b** as the dominant product in all cases. Further kinetic characterization showed that disruption of the cyclic DKP scaffold to the linear dipeptide clearly decreased the binding affinity to CpaD. Saturation kinetics could not be obtained even at 1 mM of the dipeptide substrates. The apparent turnover numbers were therefore estimated for comparing the relative catalytic efficiency of CpaD toward individual dipeptides (Table 3). Among the six substrates **9–14** tested, H-Trp-Ala-OH **9** was most efficiently converted to the corresponding product by CpaD with an observed  $k_{\text{cat}}$  of  $0.34 \text{ min}^{-1}$ , whereas H-Trp-Phe-OH **13** was least efficient with an observed  $k_{\text{cat}}$  of  $0.11 \text{ min}^{-1}$ . It is not clear from this set of experiments what is an optimized dipeptide sequence for CpaD and will be a subject for future investigation.

It appears that CpaD strictly requires the tryptophan residue in the N-terminus of the dipeptide for prenylation since H-Ala-Trp-OH, H-Gly-Trp-OH, H-Val-Trp-OH (Figure S1, supporting information), gave only trace amounts of dimethylallylated H-Ala-Trp-OH and H-Gly-Trp-OH by LC-MS analysis under the same assay conditions used for H-Trp-Ala-OH **9**. There was no detectable conversion for H-Val-Trp-OH. Surprisingly, the dominant product observed for H-Ala-Trp-OH and H-Gly-Trp-OH assay with CpaD was the released monomeric L-Trp. This result is in contrast to the previous observation that dipeptides with a C-terminal tryptophan are not preferred substrates for the aminopeptidase activity of other Trp-DMAT (45). However, we cannot conclude that this observed activity is inherent in CpaD without further detailed investigation.

CpaD was also able to dimethylallylate N-terminal tryptophan-containing oligopeptides up to the pentapeptide H-Trp-(Ala)<sub>4</sub>-OH (data not shown). However, the catalytic efficiency is much lower than that for the dipeptide H-Trp-(Ala)-OH, and the reaction was accompanied by competitive degradation of the oligopeptides. Future investigation will be directed toward the detailed examination of the possible peptidase activity versus prenylation activity of CpaD, which may provide the opportunity to use CpaD as a promiscuous catalyst for labeling of peptide substrates for biomedical applications.

### Activity of CpaD towards aromatic acid amino acid-derived tetramic acids

Since it is evident that the tetramic acid core in *cAATrp* is an important determinant for CpaD recognition, we turned to replacement of the tryptophan moiety in *cAATrp* with other aromatic scaffolds derived from natural amino acids. As the putative tyrosine *O*-DMAT gene *sidD* from sirodesmin PL biosynthesis shares good sequence homology (ca. 34%) with the Trp-DMAT 7-DMATS (21), we synthesized the tyrosine-derived tetramic acid **15** (see methods) and tested it as a substrate for CpaD (Figure 5). Incubation of **15** with an equal molar amount of DMAPP and 0.4 mol% CpaD overnight led to clean generation of a new peak by HPLC analysis (Figure 5B, lane 1–2), which was verified to be *O*-dimethylallylated **15a** by high resolution MS and <sup>1</sup>H NMR (see methods). Subsequent kinetic analysis indicates CpaD possesses reasonable kinetic parameters towards tyrosine tetramic acid **15** with  $K_M \approx 368 \mu\text{M}$  and  $k_{\text{cat}} \approx 0.52 \text{ min}^{-1}$  (Figure 5A). The resulting catalytic efficiency is ca.  $1.41 \text{ min}^{-1} \mu\text{M}^{-1}$  and slightly superior to the racemic tryptophan thiohydantoin **2**, which is the second best Trp-containing substrate for CpaD after *cAATrp*. The observed tyrosine *O*-dimethylallylation activity is unique to CpaD as FgaPT2 did not show any activity toward **15** under the identical assay condition (Figure 5B, lane 3–5). CpaD strictly requires the presence of the tetramic acid modification, as L-tyrosine alone is not a substrate for CpaD. In addition, we prepared the phenylalanine tetramic acid analogue, however it was not accepted as a substrate for C-prenylation by CpaD (data not shown).

### The N-terminal domain of CpaD is crucial for dimerization and activity

The truncated and complete CPA biosynthetic genes cluster in *A. oryzae* RIB40 and *A. flavus* NRRL3357, respectively, were originally identified by a genome mining approach using a putative CpaD sequence from *A. oryzae* A1560 strain (26,27). Our initial efforts to verify the function of CpaD by heterologous expression and *in vitro* reconstitution utilized the CpaD from *A. oryzae* RIB40 that is identical in amino acid sequence to that from *A. oryzae* A1560. However, examination of the CpaD sequence from *A. flavus* NRRL3357, (referred to here as CpaD\_*Af*) as annotated in the *Aspergillus* Comparative Database at Broad Institute (Figure S2, supporting information), revealed that it shares 92% amino acid sequence identity to CpaD in *A. oryzae* RIB40 but is truncated by 43 amino acid residues from the N-terminus. This observation prompted us to question the consequence of the missing N-terminal sequence and if the originally assigned CpaD from *A. flavus* NRRL3357 is functional.

The overproduction of CpaD\_*Af* in *E. coli* was lackluster (see methods). The dominant fraction of the overproduced CpaD\_*Af* protein is insoluble and the yield of soluble protein is ca. 0.2 mg/L (Figure S3, supporting information), corresponding to less than 1% of that observed for the CpaD from *A. oryzae* RIB40 (CpaD\_*Ao*). Moreover, the FPLC-purified CpaD\_*Af* appears monomeric in solution, in contrast to the dimeric CpaD\_*Ao*, and did not show any activity when incubated with synthetic *cAATrp* and DMAPP (Figure S3-B, supporting information). This outcome led us to speculate that the missing N-terminal sequence was required for activity and dimerization of CpaD. After careful examination of the 5' region of *cpaD* in the *A. flavus* NRRL3357 genome, we found an adjacent nucleotide sequence that would encode for the missing 43 amino acid residues. Addition of this sequence to the original CpaD\_*Af* resulted in overexpression and purification of a full length and *functional* CpaD that is dimeric in solution (Figure S3, supporting information).

The observation that deletion of the N-terminal 43 amino acids of CpaD disrupts proper folding/oligomerization in solution and results in inactive CpaD is noteworthy, as no report exists to date to correlate the oligomeric structures of fungal Trp-DMATs with their catalytic activities. To further correlate this observation to the entire family of characterized fungal Trp-DMATs, we initiated an effort to identify conserved motifs that are consequential to Trp-DMAT activity.

## Identification of a conserved set of residues across the Trp-DMAT family that are consequential to CpaD activity

In order to identify possible conserved motifs within the fungal Trp-DMAT family, we carried out the sequence alignment of all *in vitro* characterized Trp-DMATs. Including CpaD, nine other Trp-DMATs have been characterized, which cover enzymatic dimethylallylation of indole backbones in L-Trp, L-Trp-derived DKP (24), -benzodiazepinone (20), -tetramic acid (29), and -benzoquinone (19,46) at N-1, C-2, C-3, C-4, and C-7 positions. Although no C-5 and C-6 Trp-DMAT has been identified to date, the characterized Trp-DMATs represent sufficient diversity to allow identification of conserved motifs. The aromatic prenyltransferases Orf2 (47) and CloQ (48) were not included in this alignment effort, as their sequence homologies with Trp-DMATs are very low (sequence identity <15%). Previous mutagenesis studies in the context Trp-DMAT MaPT and FgaPT2 based on their homologies with Orf2 only generated limited results that two lysine residues are catalytically relevant to their activities (23,49). Multiple alignments were carried out using ClustalW (<http://www.ebi.ac.uk/clustalw/>) and subsequently visualized with ESPrict (<http://esprict.ibcp.fr/>) (Figure 6A). The alignment results showed 24 strictly conserved amino acid residues that cluster into six recognizable regions of the Trp-DMAT sequences (Figure 6B).

In studies related to *trans*-/*cis*- prenyltransferases and terpene cyclases, the critical roles of conserved polar residues (Asp, Glu, Arg, Lys) in substrate pyrophosphate binding and aromatic residues (Trp, Phe, Tyr) in the stabilization and control of cyclization as well as determination of the prenyl product chain length, have been well documented and supported by crystallography and comprehensive mutagenesis (34–36,50). Inspection of the Trp-DMAT family alignment revealed 11 conserved charged/polar residues and 7 conserved aromatic residues (Trp, Tyr). These residues thus became primary targets for subsequent mutagenesis studies in CpaD. We measured the initial maximum velocity of each mutant in comparison to wild type CpaD to determine if the mutation of the selected residue is consequential.

The eleven conserved polar/charged residues were first examined by mutating them to structurally neutral (D/E/N→L, S/T→A/V) or reverse charged (R/K→D) residues (as they may be involved in substrate binding of *cAATrp* and DMAPP). The targeted CpaD polar/charged residue mutants (Table 4) were overproduced as highly soluble in *E. coli* as CpaD wild type and dimeric in solution as estimated by size exclusion chromatography, with the exception of CpaD(D119L) which was totally insoluble. Among the ten isolated polar/charged CpaD mutants (Table 4), the activities of E93L, R104E, K191E, D250L and K260E dropped notably in a range of 20–3000 fold in comparison to wild type. These results imply that these residues are relevant to the activity of CpaD. The remaining five mutants, S95A, N97L, D181L, T203V, and R258E, did not show significant activity changes as compared to wild type.

In two separate studies by the groups of Sherman and Li, the MaPT D181, K191, K260 mutants (23), and the FgaPT2, FtmPT1 and 7-DMATS K191, D250, R258, and K260 mutants (49) were studied.<sup>2</sup> Our observations on the critical roles of the two conserved lysine residues K191 and K260 and the irrelevant role of aspartate D181 in CpaD are in accordance with the observations of both Sherman and Li. However, the roles of D250 and R258 appeared somewhat different between CpaD, FgaPT2, FtmPT1 and 7-DMATS. While the CpaD mutant D250L showed ca. 5% activity of wild type, the corresponding D→H mutants in FtmPT1 and 7-DMATS showed ca. 30% activities of wild type, suggesting polarity at this position is important. In another case, the CpaD mutant R258E showed nearly identical activity to wild type, while the corresponding R→G mutants in FgaPT2, FtmPT1 and 7-DMATS showed ca.

<sup>2</sup>The amino acid numbers quoted here are in reference to the positions in CpaD as shown in the alignment in Figure 6A.

5%, 48% and 37% activities compared to wild type, respectively. These discrepancies likely arise from the differences of the corresponding mutated residues limiting our ability to do a strict comparison. However, these discrepancies also highlight the limitations of using *relative rate* to describe the catalytic relevance of certain residues to enzyme activity. A more comprehensive approach with measurement of  $K_M$  and  $k_{cat}$  for all the substrates involved would likely be more informative albeit beyond the scope of this study.

Nevertheless, our observation that the E93L and R104E mutations in CpaD led to 1500 and 50 fold decreases in activity, respectively, is noteworthy as these residues had not been identified before by sequence comparison with aromatic prenyltransferases Orf2 and CloQ. (23,49) The magnitude of the decrease in activity of the E93L mutant is on par with those observed for the K191L and K260L mutants, suggesting E93 is of similar importance. Whether or not these residues are also relevant to other types of Trp-DMATs will need to be justified by further mutagenesis studies and/or crystal structure determination.

We next turned our attention to the seven conserved aromatic residues including two tryptophans and five tyrosines. The importance of aromatic residues in stabilization and control of the carbocation intermediates in enzyme-catalyzed transformations is well documented (51), in particular in the context of *trans*- and *cis*- prenyltransferases and related terpene cyclases (34–36,50,52–55). Enzymatic dimethylallylation of tryptophan has been characterized as an electrophilic aromatic substitution event mediated by Trp-DMAT (56), which may well require the presence of aromatic amino acid residues in the active site. Careful inspection of the crystal structure of Orf2 (47), a related aromatic prenyltransferase, suggests the presence of tyrosine residues in the pyrophosphate-binding pocket. With this hypothesis in mind, a two-step mutagenesis approach was designed. First, the conserved Tyr and Trp were mutated to Phe. Mutation of tyrosine residues that are directly involved in pyrophosphate binding should lead to a dramatic activity decrease, analogous to what was observed with the two conserved Lys residues. On the other hand, if the primary role of the conserved Trp and Tyr residues is to stabilize the cationic prenyl intermediate, we expect the Trp/Tyr→Phe will cause only moderate activity loss due to the comparable aromatic nature of Phe. As shown in Table 5, 2000–3000 fold activity loss was observed in comparison with wild type for CpaD mutants Y262F, Y346F, Y414F (entries 1–3). However, only 10–20 fold losses were observed in CpaD mutants Y193F and Y410F (entries 4–5), suggesting that Y193 and Y410 are involved in stabilizing the transient carbocation intermediate. As a second step, mutation of Y193 and Y410 to Leu (Table 5, entries 6–7) resulted in an additional >100 fold decrease in activity relative to wild type, implicating that the aromaticity of Y193 and Y410 is more critical to the activity of CpaD. While no significant changes occurred when mutating W33 and W299 to Phe and Leu (Table 5, entries 8–11), it is important to point out that the W33F mutant could not be overproduced with solubility equal to the other mutants (see methods). The W33L mutant was completely insoluble in *E. coli* and could not be isolated for characterization. (Table 5, entries 8–9).

## DISCUSSION

Filamentous fungi are prolific natural product producers that generate an astonishing array of bioactive substances, ranging from therapeutically important penicillin antibiotics, cholesterol-lowering drug statins to notorious mycotoxins aflatoxin and cyclopiazonic acid (57). The prenylated indole alkaloid framework represents a distinctive branch of fungal natural products, which contain unique and complex molecular architectures with rich bioactive profiles. Regioselective dimethylallylation of indole scaffolds by Trp-DMATs is a key step in such fungal alkaloid biosynthesis (12). This modification can occur very early in the biosynthetic pathway; for example, C-4 dimethylallylation of free L-Trp is the first committed step in ergot alkaloid biosynthesis. More frequently, prenylation occurs during the later stages

of biosynthesis after assembly of tryptophan-containing cyclic peptides or peptide-polyketide hybrids by NRPS and/or PKS, exemplified in the biosyntheses of fumitremorgin B (58), terriquione A (19) (46) and cyclopiazonic acid as described in this study. These resulting dimethylallyl decorations can further undergo enzyme-mediated oxidations and/or cyclizations to generate the condensed polycyclic scaffolds observed in many fungal prenylated natural products, such as the conversion of tricyclic  $\beta$ -CPA to pentacyclic  $\alpha$ -CPA (Figure 1) (12).

Recent advances in fungal genome sequencing, combined with the knowledge gained during *in vitro* study of DmaW (15,16), a C-4 Trp-DMAT involved in ergot alkaloid biosynthesis, has resulted in the subsequent identification and characterization of a number of fungal Trp-DMATs with substrate diversities ranging from free L-Trp to L-Trp-derived cyclic scaffolds arising from the NRPS assembly lines (24). While accumulating biochemical data on Trp-DMATs indicate their activities are independent of divalent ion cofactors that distinguish them as a distinct subset of prenyltransferases, fundamental questions remain on how they select Trp-containing substrates and perform regioselective dimethylallylations. Prior efforts using characterized Trp-DMATs as promiscuous biocatalysts have shown some promise for chemoenzymatic preparations of regiospecifically prenylated L-Trp and L-Trp-containing DKP derivatives (44); however, their apparently inherent aminopeptidase activity has limited their utility in dimethylallylated linear L-Trp peptides (45).

Cyclopiazonic acid (CPA) is a mycotoxin that selectively blocks the sarcoplasmic reticulum  $\text{Ca}^{2+}$  ATPase with nanomolar potency (25). Isolated from various *Aspergillus* and *Penicillium* species, the  $\alpha$ -CPA end product has a rigid pentacyclic indole tetramic acid scaffold.  $\alpha$ -CPA arises from a short three-enzyme pathway, making it unique both structurally and biosynthetically among the fungal prenylated alkaloids (26,27). The first CPA pathway-specific enzyme is the hybrid PKS-NRPS CpaS, where the C-terminal redox-incompetent reductase serves as a Dieckmann cyclization catalyst to release L-cAATrp (29). Regioselective dimethylallylation of L-cAATrp at C4 of the indole ring by the action of the DMAT CpaD constitutes the second pathway-specific step, and the resulting  $\beta$ -CPA is further oxidatively tailored by the flavoenzyme CpaO to form two rings in one step.

In this study, we first cloned CpaD from *A. oryzae* RIB40, heterologously overexpressed it in *E. coli*, and obtained soluble homodimeric enzyme in good yield. Synthetic L-cAATrp was validated as a substrate for CpaD with a  $K_M$  of  $109 \pm 16 \mu\text{M}$  and a  $k_{\text{cat}}$  of  $53 \pm 12 \text{ min}^{-1}$ . While CpaD showed clear kinetic preference for L-cAATrp over D-cAATrp in a 24 fold difference in catalytic efficiency, it virtually does not accept L-Trp as substrate with an estimated  $k_{\text{cat}}/K_M < 4 \times 10^{-6} \mu\text{M}^{-1} \text{ min}^{-1}$ , more than a  $10^5$  fold decrease from L-cAATrp. This observation distinguishes CpaD from the Trp-DMATs FtmPT1 and CdpNPT that utilize Trp-containing DKPs as their native substrate (18,22) yet readily modify free L-Trp (37). This highlights the critical importance of the tetramic acid ring as a recognition element in cAATrp for CpaD catalysis.

Subsequent exploration of substrate promiscuity for CpaD started with Trp-containing thiohydantoin as mimics of the five-membered heterocyclic tetramic acid, then the Trp-containing DKPs with a six-membered cyclic peptide scaffold, and ultimately to linear Trp-containing dipeptides. Kinetic studies showed a trend of decreased catalytic efficiency on these substrate analogues for CpaD compared to the tetramic acid moiety in L-cAATrp. Despite the diminished efficiency of CpaD toward Trp-containing thiohydantoin, DKPs, and linear dipeptides, synthetically useful conversion rates (60–100%) were obtained when using 0.4 mol % CpaD over a 24-hour incubation period, making CpaD a candidate biocatalyst for chemoenzymatic preparations of C-4 dimethylallylated Trp-containing molecules with similar scaffolds. Moreover, CpaD showed negligible aminopeptidase activity toward N-terminal Trp-containing dipeptides in the absence of divalent cation, in contrast to other fungal Trp-DMATs,

and thus allows access to several C-4 dimethylallylated Trp-containing dipeptides. It is also noteworthy that CpaD is able to dimethylallylate the pentapeptide H-Trp-(Ala)<sub>4</sub>-OH albeit with competitive degradation of the starting peptide. Minimization of Trp-DMAT aminopeptidase activity will likely expand the utility of this family of enzymes. Indication of the tetramic acid as a substrate recognition element was demonstrated by the ability of CpaD to O-prenylate rather than C-prenylate during generation of the *O*-dimethylallyl tyrosine-derived tetramic acid.

We have shown that truncation of the N-terminal CpaD sequence is detrimental to activity in an effort to verify the function of the erroneously predicted sequence of CpaD from *A. flavus* NRRL3357. This subsequently led us to compare all characterized Trp-DMATs in search of conserved sequence motifs. A sequence alignment using ClustalW revealed 24 strictly conserved amino acid residues in six recognizable motifs across the Trp-DMAT family. Based on prior studies on the related *trans*-, *cis*-prenyltransferases and terpene cyclases, we chose eleven conserved polar/charged residues and seven conserved aromatic residues to mutagenize and assay for CpaD activity. CpaD mutants generated from five polar/charged residues (E93L, R104E, K191E, D250L and K260E) and five tyrosine residues (Y193L, Y262F, Y346F, Y410L, Y414F) led to 20–3000 fold reductions in activity compared to wild type, implicating these residues in binding with either substrate and/or stabilization of the carbocation intermediate. These ten residues are evenly distributed in five of the six conserved motifs and will serve as signatures for gene probes to identify new fungal Trp-DMATs that are involved in as of yet uncharacterized prenylated indole alkaloid biosynthesis.

During the preparation of this manuscript, the crystal structure of the C-4 Trp-DMAT FgaPT2 was reported (59). Our mutagenesis efforts leading to the identification of the above ten residues in CpaD largely correlate with predictions enabled by the FgaPT2 structure. E93 in CpaD is likely involved in the binding of the L-*c*AATrp Trp-N-1 atom analogous to the E89 residue observed for FgaPT2, whereas the remaining polar/charged residues R104, K191, D250, K260 and tyrosine residues Y193, Y262, Y346, Y410, Y414 are likely located in the binding pocket of DMAPP. The FgaPT2 structure and the comprehensive mutagenesis efforts described here provide insight into a common binding mode for the DMAPP prenyl donor. However, it is still unresolved how Trp-DMAT family members differentiate between tryptophan substrates, direct regioselectivity and selectively utilize the C5 prenyl donor, emphasizing the value of additional structural and biochemical characterization. In the related families of *trans*-, *cis*-prenyltransferases and terpene cyclases, such combined efforts have led to a deeper understanding of specificity and mechanism (34–36,50,60–63). Given the architectural complexity of the prenylated indole natural product scaffolds and their diverse biologic activities, a comparable set of insights into this subclass of prenyl transferases would prove useful during efforts to reprogram these biosynthetic pathways.

The intriguing substrate promiscuity of CpaD warrants a more detailed understanding of how CpaD functions at the molecular level, especially in comparison to other Trp-DMATs, which will enable future engineering efforts to improve its inherent utility as a biocatalyst. Additionally, further understanding of characteristics critical to Trp-DMATs as a family, such as the characterization of conserved sequence motifs described here, will facilitate the discovery of related prenylation enzymes and new natural products.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank Dr. Kevin McCluskey (FGSC) and Dr. Jiujiang Yu (USGA) for providing the NRRL3357 strain and its genomic DNA, Prof. Robert Williams (Colorado State University) for providing brevianamide F and Dr. Heidi Imker for proofreading.

## Abbreviations

<b>CPA</b>	cyclopiazonic acid
<b>cAATrp</b>	<i>cyclo</i> -acetoacetyl-L-tryptophan
<b>PKS</b>	polyketide synthase
<b>NRPS</b>	nonribosomal peptide synthetase
<b>DMAPP</b>	dimethylallyl pyrophosphate, IPP, isopentenyl pyrophosphate
<b>GPP</b>	geranyl pyrophosphate
<b>FPP</b>	farnesyl pyrophosphate
<b>GGPP</b>	geranylgeranyl pyrophosphate
<b>DKP</b>	diketopiperazine
<b>DMAT</b>	dimethylallyltransferase

## References


1. Aniszewski, T. *Alkaloids - Secrets of Life: Alkaloid Chemistry, Biological Significance, Applications and Ecological Role*. Elsevier Science; Amsterdam: 2007.
2. Haarmann T, Rolke Y, Giesbert S, Tudzynski P. Ergot: from witchcraft to biotechnology. *Mol Plant Pathol* 2009;10:563–577. [PubMed: 19523108]
3. Cui CB, Kakeya H, Okada G, Onose R, Osada H. Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by *Aspergillus fumigatus*. I. Taxonomy, fermentation, isolation and biological properties. *J Antibiot* 1996;49:527–533. [PubMed: 8698634]
4. Qian-Cutrone J, Huang S, Shu Y-Z, Vyas D, Fairchild C, Menendez A, Krampitz K, Dalterio R, Klohr SE, Gao Q. Stephacidin A and B: two structurally novel, selective inhibitors of the testosterone-dependent prostate LNCaP cells. *J Am Chem Soc* 2002;124:14556–14557. [PubMed: 12465964]
5. Shoop WL, Haines HW, Eary CH, Michael BF. Acute toxicity of paraherquamide and its potential as an anthelmintic. *Am J Vet Res* 1992;53:2032–2034. [PubMed: 1466498]
6. Gallagher RT, Clardy J, Wilson BJ. Aflatrem, a tremorgenic toxin from *Aspergillus flavus*. *Tetrahedron Lett* 1980;21:239–242.
7. Holzapfel CW. Isolation and Structure of Cyclopiazonic Acid a Toxic Metabolite of *Penicillium Cyclopium* Westling. *Tetrahedron* 1968;24:2101–2119. [PubMed: 5636916]
8. Saikia S, Nicholson MJ, Young C, Parker EJ, Scott B. The genetic basis for indole-diterpene chemical diversity in filamentous fungi. *Mycol Res* 2008;112:184–199. [PubMed: 18262778]
9. He J, Wijeratne EMK, Bashyal BP, Zhan J, Seliga CJ, Liu MX, Pierson EE, Pierson LS, Van Etten HD, Gunatilaka AAL. Cytotoxic and other metabolites of *Aspergillus* inhabiting the rhizosphere of Sonoran desert plants. *J Nat Prod* 2004;67:1985–1991. [PubMed: 15620238]
10. Brewer D, Jerram WA, Meiler D, Taylor A. The toxicity of cochliodinol, an antibiotic metabolite of *Chaetomium* spp. *Can J Microbiol* 1970;16:433–440. [PubMed: 4987295]
11. Mocek U, Schultz L, Buchan T, Baek C, Fretto L, Nzerem J, Sehl L, Sinha U. Isolation and structure elucidation of five new asterriquinones from *Aspergillus*, *Humicola* and *Botryotrichum* species. *J Antibiot* 1996;49:854–859. [PubMed: 8931717]

12. Williams R, Stocking E, Sanz-Cervera J. Biosynthesis of prenylated alkaloids derived from tryptophan. *Top Curr Chem* 2000;209:97–173.
13. Williams RM, Cox RJ. Paraherquamides, brevipamides, and asperparalines: laboratory synthesis and biosynthesis. An interim report. *Acc Chem Res* 2003;36:127–139. [PubMed: 12589698]
14. Lee S-L, Floss HG, Heinstejn P. Purification and properties of dimethylallylpyrophosphate:tryptophan dimethylallyl transferase, the first enzyme of ergot alkaloid biosynthesis in *Claviceps* sp. SD 58. *Arch Biochem Biophys* 1976;177:84–94. [PubMed: 999297]
15. Tsai HF, Wang H, Gebler JC, Poulter CD, Schardl CL. The *Claviceps purpurea* gene encoding dimethylallyltryptophan synthase, the committed step for ergot alkaloid biosynthesis. *Biochem Biophys Res Commun* 1995;216:119–125. [PubMed: 7488077]
16. Gebler JC, Poulter CD. Purification and characterization of dimethylallyl tryptophan synthase from *Claviceps purpurea*. *Arch Biochem Biophys* 1992;296:308–313. [PubMed: 1605639]
17. Unsold IA, Li SM. Reverse prenyltransferase in the biosynthesis of fumigaclavine C in *Aspergillus fumigatus*: Gene expression, purification, and characterization of fumigaclavine C synthase FGAPT1. *ChemBioChem* 2006;7:158–164. [PubMed: 16397874]
18. Grundmann A, Li SM. Overproduction, purification and characterization of FtmPT1, a brevipamide F prenyltransferase from *Aspergillus fumigatus*. *Microbiology* 2005;151:2199–2207. [PubMed: 16000710]
19. Schneider P, Weber M, Hoffmeister D. The *Aspergillus nidulans* enzyme TdiB catalyzes prenyltransfer to the precursor of bioactive asterriquinones. *Fungal Genet Biol* 2008;45:302–309. [PubMed: 18029206]
20. Yin WB, Grundmann A, Cheng J, Li SM. Acetylaszonalenin biosynthesis in *Neosartorya fischeri*. Identification of the biosynthetic gene cluster by genomic mining and functional proof of the genes by biochemical investigation. *J Biol Chem* 2009;284:100–109. [PubMed: 19001367]
21. Kremer A, Westrich L, Li SM. A 7-dimethylallyltryptophan synthase from *Aspergillus fumigatus*: overproduction, purification and biochemical characterization. *Microbiology* 2007;153:3409–3416. [PubMed: 17906140]
22. Ruan HL, Yin WB, Wu JZ, Li SM. Reinvestigation of a cyclic dipeptide N-prenyltransferase reveals rearrangement of N-1 prenylated indole derivatives. *ChemBioChem* 2008;9:1044–1047. [PubMed: 18383240]
23. Ding YS, Williams RM, Sherman DH. Molecular analysis of a 4-dimethylallyltryptophan synthase from *Malbranchea aurantiaca*. *J Biol Chem* 2008;283:16068–16076. [PubMed: 18390548]
24. Steffan N, Grundmann A, Yin W-B, Kremer A, Li S-M. Indole prenyltransferases from fungi: a new enzyme group with high potential for the production of prenylated indole derivatives. *Curr Med Chem* 2009;16:218–231. [PubMed: 19149573]
25. Seidler NW, Jona I, Vegh M, Martonosi A. Cyclopiazonic acid is a specific inhibitor of the Ca<sup>2+</sup>-ATPase of sarcoplasmic reticulum. *J Biol Chem* 1989;264:17816–17823. [PubMed: 2530215]
26. Chang PK, Horn BW, Dorner JW. Clustered genes involved in cyclopiazonic acid production are next to the aflatoxin biosynthesis gene cluster in *Aspergillus flavus*. *Fungal Genet Biol* 2009;46:176–182. [PubMed: 19038354]
27. Tokuoka M, Seshime Y, Fujii I, Kitamoto K, Takahashi T, Koyama Y. Identification of a novel polyketide synthase-nonribosomal peptide synthetase (PKS-NRPS) gene required for the biosynthesis of cyclopiazonic acid in *Aspergillus oryzae*. *Fungal Genet Biol* 2008;45:1608–1615. [PubMed: 18854220]
28. Holzapfel CW, Wilkins DC. On the Biosynthesis of Cyclopiazonic Acid. *Phytochemistry* 1971;10:351–358.
29. Liu X, Walsh C. Cyclopiazonic Acid Biosynthesis in *Aspergillus* sp.: Characterization of a Reductase-like R\* Domain in Cyclopiazonate Synthetase That Forms and Releases cyclo-Acetoacetyl-l-tryptophan. *Biochemistry* 2009;48:8746–8757. [PubMed: 19663400]
30. Schobert R, Schlenk A. Tetramic and tetronic acids: An update on new derivatives and biological aspects. *Bioorg Med Chem* 2008;16:4203–4221. [PubMed: 18334299]
31. Sambrook, J.; Russell, D. *Molecular Cloning: A Laboratory Manual*. Vol. 3. Cold Spring Harbor Laboratory Press; Plainville, NY: 2001.




32. Neethling DC, McGrath RM. Metabolic Development and Mitochondrial Changes during Cyclopiiazonic Acid Production in *Penicillium-Cyclopiium*. *Can J Microb* 1977;23:856–872.
33. Christensen, BE.; Mollgaard, H.; Kaasgaard, S.; Lehmbek, J. Methods for producing polypeptides in *Aspergillus* mutant cells. US Patent. 7,241,614. 2007.
34. Takahashi S, Koyama T. Structure and function of cis-prenyl chain elongating enzymes. *Chem Rec* 2006;6:194–205. [PubMed: 16900467]
35. Poulter CD. Farnesyl Diphosphate Synthase. A Paradigm for Understanding Structure and Function Relationships in E-polyprenyl Diphosphate Synthases. *Phytochem Rev* 2006;5:17–26.
36. Liang P-H, Ko T-P, Wang AH-J. Structure, mechanism and function of prenyltransferases. *Eur J Biochem* 2002;269:3339–3354. [PubMed: 12135472]
37. Zou H, Zheng X, Li S-M. Substrate promiscuity of the cyclic dipeptide prenyltransferases from *Aspergillus fumigatus*. *J Nat Prod* 2009;72:44–52. [PubMed: 19113967]
38. Steffan N, Unsold IA, Li SM. Chemoenzymatic synthesis of prenylated indole derivatives by using a 4-dimethylallyltryptophan synthase from *Aspergillus fumigatus*. *ChemBioChem* 2007;8:1298–1307. [PubMed: 17577899]
39. Markert A, Steffan N, Ploss K, Hellwig S, Steiner U, Drewke C, Li S-M, Boland W, Leistner E. Biosynthesis and accumulation of ergoline alkaloids in a mutualistic association between *Ipomoea asarifolia* (Convolvulaceae) and a clavicipitalean fungus. *PLANT PHYSIOLOGY* 2008;147:296–305. [PubMed: 18344419]
40. Teng X, Degterev A, Jagtap P, Xing X, Choi S, Denu R, Yuan J, Cuny GD. Structure-activity relationship study of novel necroptosis inhibitors. *Bioorg Med Chem Lett* 2005;15:5039–5044. [PubMed: 16153840]
41. Inoue S, Murata J, Takamatsu N, Nagano H, Kishi Y. Synthetic studies on echinulin and related natural products. V. Isolation, structure and synthesis of echinulin-neoechinulin type alkaloids isolated from *Aspergillus amstelodami*. *Yakugaku Zasshi* 1977;97:576–581. [PubMed: 560465]
42. Yamazaki M, Fujimoto H, Kawasaki T. Chemistry of tremorgenic metabolites. I. Fumitremorgin A from *Aspergillus fumigatus*. *Chem Pharm Bull* 1980;28:245–254. [PubMed: 6988091]
43. Okada M, Yamaguchi H, Sato I, Tsuji F, Dubnau D, Sakagami Y. Chemical structure of posttranslational modification with a farnesyl group on tryptophan. *Biosci Biotechnol Biochem* 2008;72:914–918. [PubMed: 18323630]
44. Li S. Applications of dimethylallyltryptophan synthases and other indole prenyltransferases for structural modification of natural products. *Appl Microbiol Biotechnol* 2009;84:631–639. [PubMed: 19633837]
45. Kremer A, Li SM. Tryptophan aminopeptidase activity of several indole prenyltransferases from *Aspergillus fumigatus*. *Chem Biol* 2008;15:729–738. [PubMed: 18635009]
46. Balibar CJ, Howard-Jones AR, Walsh CT. Terrequinone A biosynthesis through L-tryptophan oxidation, dimerization and bisprenylation. *Nat Chem Biol* 2007;3:584–592. [PubMed: 17704773]
47. Kuzuyama T, Noel JP, Richard SB. Structural basis for the promiscuous biosynthetic prenylation of aromatic natural products. *Nature* 2005;435:983–987. [PubMed: 15959519]
48. Pojer F, Wemakor E, Kammerer B, Chen H, Walsh CT, Li S-M, Heide L. CloQ, a prenyltransferase involved in clorobiocin biosynthesis. *Proc Natl Acad Sci USA* 2003;100:2316–2321. [PubMed: 12618544]
49. Stec E, Steffan N, Kremer A, Zou HX, Zheng XD, Li SM. Two lysine residues are responsible for the enzymatic activities of indole prenyltransferases from fungi. *ChemBioChem* 2008;9:2055–2058. [PubMed: 18677738]
50. Christianson DW. Structural biology and chemistry of the terpenoid cyclases. *Chem Rev* 2006;106:3412–3442. [PubMed: 16895335]
51. Gallivan JP, Dougherty DA. Cation- $\pi$  interactions in structural biology. *Proc Natl Acad Sci USA* 1999;96:9459–9464. [PubMed: 10449714]
52. Forcat S, Allemann RK. Dual role for phenylalanine 178 during catalysis by aristolochene synthase. *Chem Commun* 2004:2094–2095.
53. Deligeorgopoulou A, Taylor SE, Forcat S, Allemann RK. Stabilisation of eudesmane cation by tryptophan 334 during aristolochene synthase catalysis. *Chem Commun* 2003:2162–2163.


54. Calvert MJ, Ashton PR, Allemann RK. Germacrene A is a product of the aristolochene synthase-mediated conversion of farnesylpyrophosphate to aristolochene. *J Am Chem Soc* 2002;124:11636–11641. [PubMed: 12296728]
55. Calvert MJ, Taylor SE, Allemann RK. Tyrosine 92 of aristolochene synthase directs cyclisation of farnesyl pyrophosphate. *Chem Commun* 2002:2384–2385.
56. Gebler JC, Woodside A, Poulter CD. Dimethylallyltryptophan Synthase. An Enzyme-Catalyzed Electrophilic Aromatic Substitution. *J Am Chem Soc* 1992;114:7354–7360.
57. Cole, R.; Schweikert, M.; Jarvis, B. *Handbook of Secondary Fungal Metabolites*. Elsevier; San Diego: 2003.
58. Grundmann A, Kuznetsova T, Afiyatullof SS, Li SM. FtmPT2, an N-prenyltransferase from *Aspergillus fumigatus*, catalyses the last step in the biosynthesis of fumitremorgin B. *ChemBioChem* 2008;9:2059–2063. [PubMed: 18683158]
59. Metzger U, Schall C, Zoicher G, Unsöld I, Stec E, Li S-M, Heide L, Stehle T. The structure of dimethylallyl tryptophan synthase reveals a common architecture of aromatic prenyltransferases in fungi and bacteria. *Proc Natl Acad Sci USA* 2009;106:14309–14314. [PubMed: 19706516]
60. Thulasiram HV, Erickson HK, Poulter CD. A common mechanism for branching, cyclopropanation, and cyclobutanation reactions in the isoprenoid biosynthetic pathway. *J Am Chem Soc* 2008;130:1966–1971. [PubMed: 18198872]
61. O'Maille PE, Malone A, Dellas N, Andes Hess B, Smentek L, Sheehan I, Greenhagen BT, Chappell J, Manning G, Noel JP. Quantitative exploration of the catalytic landscape separating divergent plant sesquiterpene synthases. *Nat Chem Biol* 2008;4:617–623. [PubMed: 18776889]
62. Christianson DW. Unearthing the roots of the terpenome. *Curr Opin Chem Biol* 2008;12:141–150. [PubMed: 18249199]
63. Thulasiram HV, Erickson HK, Poulter CD. Chimeras of two isoprenoid synthases catalyze all four coupling reactions in isoprenoid biosynthesis. *Science* 2007;316:73–76. [PubMed: 17412950]

**Figure 1.**


Cyclopiiazonic acid (CPA) biosynthesis in *Aspergillus sp.* (A) Functions of CPA biosynthetic genes CpaS, CpaD and CpaO (B) CPA gene cluster organization in CPA producing/CPA(+) strain *A. flavus* NRRL3357 and CPA nonproducing/CPA(-) strain *A. oryzae* RIB40.




**Figure 2.** *In vitro* validation of the function of CpaD. (A) Heterologously overexpressed and purified CpaD from *A. oryzae* RIB40. (B) HPLC traces that indicate CpaD is able to convert *cAATrp* to  $\beta$ -CPA in the presence of DMAPP. (C) Comparison of CpaD activity with or without addition of divalent metals and EDTA.




**Figure 3.** Tryptophan thiohydantoin derivatives (**1–3**) and tryptophan containing diketopeperazines (DKPs) (**4–8**) as substrates for CpaD. Schemes illustrating the regioselective prenylation of tryptophan thiohydantoin **1–3** (A) and tryptophan DKPs **4–8** by CpaD (B). HPLC assay demonstrating the conversion of tryptophan thiohydantoin **2** and Trp-Phe DKP **5** to the corresponding prenylated products by CpaD (C).

**Figure 4.**

N-terminal tryptophan containing dipeptides **9–14** as substrates for CpaD. (A) Schemes illustrating the different reaction outcomes catalyzed by CpaD and FgaPT2 when using H-Trp-Ala-OH **9** as substrate. (B) HPLC traces showing the effective conversion of the dipeptide H-Trp-Ala-OH **9** to the corresponding prenylated product **9a** by CpaD compared to FgaPT2 that gave **9b**.



**Figure 5.** Tyrosine derived tetramic acid is a substrate for CpaD. (A) Scheme illustrating the CpaD-catalyzed *O*-prenylation of the tyrosine derived tetramic acid **15** to give **15a**. (B) HPLC traces showing the effective conversion of **15** to **15a** catalyzed by CpaD, but not FgaPT2. Unmodified L-tyrosine is not a substrate for CpaD.



**Figure 6.** Identification of conserved motifs in the Trp-DMAT family. (A) ClustalW alignment of all functionally validated Trp-DMATs. Red stars indicate exclusively conserved amino acid residues. (B) Representation of conserved motifs within the Trp-DMAT family. Numbers correspond to the amino acid residues in CpaD. The bold amino acid residues correspond to those subjected to mutagenesis.



Table 1

Kinetic parameters of CpaD with its native substrate L-cAAATrp, the enantiomer D-cAAATrp, L-Trp and D-Trp.

Substrate	Product Identification		$K_m$ ( $\mu\text{M}$ )	Kinetic profile	
	$[\text{M}+\text{H}]^+_{\text{cal.}}$	$[\text{M}+\text{H}]^+_{\text{obs.}}$		$k_{\text{cat}}$ ( $\text{min}^{-1}$ )	$k_{\text{cat}}/K_m$ ( $\text{min}^{-1} \mu\text{M}^{-1}$ )
L-cAAATrp	339.1709	339.1713	$109 \pm 16$	$53 \pm 12$	0.486
D-cAAATrp	339.1709	339.1712	$382 \pm 29$	$8.2 \pm 1.9$	0.021
L-Trp <sup>a</sup>	273.1603	273.1601	>1000	$4.1 \times 10^{-3}$	$< 4.1 \times 10^{-6}$
D-Trp <sup>a</sup>	273.1603	273.1605	>1000	$7.8 \times 10^{-4}$	$< 7.8 \times 10^{-7}$

Kinetic parameters of CpaD with tryptophan thiohydantoin **1–3** and tryptophan containing DKPs **4–8**.

**Table 2**

Substrate	Product <b>1a–8a</b>		$K_m$ ( $\mu\text{M}$ )	Kinetic profile	
	$[\text{M}+\text{H}]^+_{\text{cal}}$	$[\text{M}+\text{H}]^+_{\text{obs}}$		$k_{\text{cat}}$ ( $\text{min}^{-1}$ )	$k_{\text{cat}}/K_m$ ( $\text{min}^{-1} \mu\text{M}^{-1}$ )
<b>1</b>	328.1484	328.1480	$383 \pm 32$	$0.27 \pm 0.06$	$7.05 \times 10^{-4}$
<b>2</b>	314.1327	314.1325	$315 \pm 28$	$0.34 \pm 0.05$	$10.8 \times 10^{-4}$
<b>3</b>	390.1640	390.1644	$502 \pm 36$	$0.14 \pm 0.03$	$2.79 \times 10^{-4}$
<b>4</b>	312.1712	312.1717	$712 \pm 38$	$0.18 \pm 0.04$	$2.54 \times 10^{-4}$
<b>5</b>	402.2182	402.2185	$546 \pm 42$	$0.29 \pm 0.06$	$5.31 \times 10^{-4}$
<b>6</b>	418.2131	418.2132	$526 \pm 34$	$0.32 \pm 0.08$	$6.08 \times 10^{-4}$
<b>7</b>	441.2291	441.2296	$638 \pm 46$	$0.21 \pm 0.05$	$3.29 \times 10^{-4}$
<b>8</b>	352.2025	352.2022	$756 \pm 52$	$0.12 \pm 0.05$	$1.59 \times 10^{-4}$

**Table 3**

Activity profiles of CpaD with N-terminal Trp-containing dipeptides.

Substrate	Product Identification		<i>observed</i> $v_i$ ( $\text{min}^{-1}$ ) <sup>a</sup>
	$[\text{M}+\text{H}]^+_{\text{cal.}}$	$[\text{M}+\text{H}]^+_{\text{obs.}}$	
<b>9</b> (H-Trp-Ala-OH)	344.1974	344.1977	$0.34 \pm 0.06$
<b>10</b> (H-Trp-Gly-OH)	330.1818	330.1812	$0.16 \pm 0.05$
<b>11</b> (H-Trp-Val-OH)	304.1661	304.1665	$0.31 \pm 0.07$
<b>12</b> (H-Trp-Leu-OH)	386.2444	386.2449	$0.18 \pm 0.04$
<b>13</b> (H-Trp-Phe-OH)	352.1661	352.1666	$0.11 \pm 0.03$
<b>14</b> (H-Trp-Tyr-OH)	368.1610	368.1613	$0.22 \pm 0.05$

<sup>a</sup> Saturation kinetics could not be achieved even with 1 mM of **9–14** as substrates, therefore observed maximum initial velocity for these substrates is shown.

**Table 4**

Relative activity profiles of polar/charged CpaD mutants targeted by examination of conserved motifs in the Trp-DMAT family.<sup>a</sup>

Entry	CpaD protein	$v_i^{\text{rel}}$
1	<b>E93L</b>	$(6.8 \pm 0.7) \times 10^{-4}$
2	S95A	$0.92 \pm 0.11$
3	N97L	$0.63 \pm 0.15$
4	<b>R104E</b>	$(2.1 \pm 0.3) \times 10^{-2}$
5	D119L	—
6	D181L	$0.47 \pm 0.03$
7	<b>K191E</b>	$(2.7 \pm 0.5) \times 10^{-4}$
8	T203V	$0.96 \pm 0.08$
9	<b>D250L</b>	$(5.1 \pm 0.6) \times 10^{-2}$
10	R258E	$0.92 \pm 0.12$
11	<b>K260E</b>	$(3.2 \pm 0.4) \times 10^{-4}$

<sup>a</sup>  $v_i^{\text{rel}}$  is the relative observed maximum initial velocity of each mutant CpaD to that of wild type, which is defined as 1. Mutants in bold are those with a notable decrease in relative activity. D119L could not be overproduced in soluble form for characterization.

**Table 5**

Relative activity profiles of aromatic CpaD mutants targeted by examination of conserved motifs in the Trp-DMAT family.<sup>a</sup>

Entry	CpaD protein	$v_i^{\text{rel}}$
1	Y193F	$(5.3 \pm 0.6) \times 10^{-2}$
2	Y262F	$(3.6 \pm 0.8) \times 10^{-4}$
3	Y346F	$(4.9 \pm 0.3) \times 10^{-4}$
4	Y410F	$0.12 \pm 0.02$
5	Y414F	$(2.8 \pm 0.4) \times 10^{-4}$
6	Y193L	$(4.3 \pm 0.3) \times 10^{-4}$
7	Y410L	$(7.2 \pm 0.6) \times 10^{-4}$
8	W33F	$0.42 \pm 0.06$
9	W33L	—
10	W299F	$0.92 \pm 0.07$
11	W299L	$0.38 \pm 0.05$

<sup>a</sup>  $v_i^{\text{rel}}$  is the relative observed maximum initial velocity of each mutant CpaD to that of wild type, which is defined as 1. W33L could not be overproduced in soluble form for characterization.